Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960–2014: A population-based cohort study

Leandersson, Pia; Högberg, Thomas; Dickman, Paul W.; Malander, Susanne; Borgfeldt, Christer

doi:10.1186/s12885-021-08169-w

Cited by 4 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This kind of uneven improvement for survival offers an excellent justification for conditional survival analysis. Similar conclusions of no long-term survival improvement were reached by analysing 10-year survival in the Netherlands, and later in Sweden [ 7 , 20 ]. Another way of estimating periodic differences in survival is to simply compare the differences between 1- and 5-year survival at different times.…”

Section: Discussionsupporting

confidence: 62%

“…Age differences in ovarian cancer survival have been reported in earlier studies, including the recent DK and SE studies [20,24]. The DK study discussed the evidence and the theories for the age disparity, considering limited offered treatment, toleration of treatment, late stage disease at presentation, tumor biological differences and comorbidities [24].…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Survival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries

Hemminki,

Zitricky,

Försti

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Despite treatment having improved through intensive surgical procedures and chemotherapy—and more recently, targeted therapies—ovarian cancer is the most fatal female cancer. As such, we wanted to analyze age-specific survival trends for ovarian cancer in Denmark, Finland, Norway and Sweden over the past 50 years, with a special aim of comparing survival development between the age groups. Methods: We modelled survival data from the NORDCAN database for 1-, 5- and conditional 5/1-year relative (between years 1 and 5) survival for ovarian cancer from 1972 to 2021. Results: Young patients had a 70% 5-year survival while the survival was only 30% for the oldest patients. Conditional survival showed that survival between years 1 and 5 did not improve for patients older than 60 years throughout the 50-year period, during which time the gaps between the youngest and the oldest patients widened. Conclusions: Improvement in 1-year survival was so large that it masked the modest development between years 1 and 5, resulting in a widening age disparity in 5-year survival. The current treatment practices, which appear increasingly effective for younger patients, have not helped remedy the large age differences in ovarian cancer survival. Early detection methods and therapeutic innovations are urgently needed, and aged patients need a special focus.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 90%

Survival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries

Hemminki,

Zitricky,

Försti

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…The 5-year survival rate of ovarian cancer has remained in the range of 40-50% in the past 20 years despite diagnostic and therapeutic advancements [2,3]. When diagnosed early, the prognosis of ovarian cancer is much better, with a 5-year survival rate of 73-92% for tumors diagnosed at stage I, compared to < 6% for tumors diagnosed at stage IV [4,5].…”

Section: Introductionmentioning

confidence: 99%

Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer

Dobilas

Chen

Alcaide

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background Circulating tumor DNA (ctDNA), which is shed from tumor cells into the blood, is a promising minimal-invasive method for cancer diagnostics and monitoring. The aim of this study was to evaluate preoperative ctDNA levels in the plasma of patients with ovarian cancer and correlate the levels to clinicopathological parameters and patient outcome. Methods Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples, obtained prior to surgery, to evaluate ctDNA levels in terms of mutant copy number/mL and variant allele frequency. Results Somatic mutations were found in 24 tumors, of which seven were from patients with borderline, and 17 with invasive cancer diagnosis. TP53 was the most frequently mutated gene. Fifteen of 24 patients had detectable ctDNA levels in pre-operative plasma. Plasma ctDNA mutant concentration increased with higher stage (ptrend <0.001). Cancer patients with more than 10 ctDNA mutant copies/mL in plasma prior to surgery had significantly worse overall survival (p = 0.008). Conclusions Measuring ctDNA in pre-operative plasma may be useful as a predictive biomarker for tumor staging and prognosis in ovarian cancer patients.

show abstract

“…Interval debulking surgery (IDS) is used to reduce the number of tumour cells and is typically followed by neoadjuvant chemotherapy (NACT), including carboplatin and paclitaxel [12][13][14][15][16]. But OVCA patients often still meet with an unfavourable prognosis due to late diagnosis [17][18][19][20][21]. Further study of the mechanism of OVCA will be helpful to find effective measures for early diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods

Liang

Luo

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Introduction: We aimed to explore the abnormal expression of dual-specificity protein phosphatase 1 (DUSP1) and its latent molecular mechanisms in ovarian carcinoma (OVCA).Materials and Methods: Two clinical cohorts collected from two different hospitals were used to evaluate the expression of DUSP1 protein in OVCA tissues. RNA-sequencing and microarray datasets were utilised to verify DUSP1 expression at mRNA levels in both OVCA tissues and in the peripheral blood of OVCA patients. Furthermore, an integrated calculation was performed to pool the standard mean difference (SMD) from each cohort in order to comprehensively assess the expression of DUSP1 in OVCA. Furthermore, we examined the relationship among DUSP1, tumour microenvironment (TME), and chemotherapy resistance in OVCA. Moreover, we used pathway enrichment analysis to explore the underlying mechanisms of DUSP1 in OVCA.Results: A pooled SMD of −1.19 (95% CI [−2.00, −0.38], p = 0.004) with 1,240 samples revealed that DUSP1 was downregulated in OVCA at both mRNA and protein levels. The area under the receiver operating characteristic curve of 0.9235 indicated the downregulated DUSP1 in peripheral blood may have a non-invasive diagnostic value in OVCA. Through six algorithms, we identified that DUSP1 may related to tumour-infiltrating T cells and cancer associated fibroblasts (CAFs) in OVCA. Pathway enrichment demonstrated that DUSP1 might participate in the mitogen-activated protein kinase (MAPK) signalling pathway. Furthermore, DUSP1 may have relations with chemotherapy resistance, and a favourable combining affinity was observed in the paclitaxel-DUSP1 docking model.Conclusion: DUSP1 was downregulated in OVCA, and this decreasing trend may affect the infiltration of CAFs. Finally, DUSP1 may have a targeting relation with paclitaxel and participate in MAPK signaling pathways.

show abstract

Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960–2014: A population-based cohort study

Cited by 4 publications

References 29 publications

Survival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries

Survival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries

Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer

Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods

Contact Info

Product

Resources

About